LIFE SAVING DRUGS PROGRAM EXPERT PANEL

18th MEETING: 28 June 2024

**AGENDA**

1. **Standing business**
   1. Welcome, apologies and Conflicts of Interest
   2. Update on actions from previous meetings
   3. Correspondence
   4. Report from the Secretariat
2. **24 month review of existing LSDP medicines**
   1. Avalglucosidase alfa (Nexviazyme®) – for the treatment of Pompe disease
3. **Other business**
   1. HTA Policy and Methods Review
   2. Expansion of the newborn bloodspot screening program: Implications for the LSDP

Note: There are no applications for new listings being discussed at this meeting.